As part of our Biotechnology Report we spoke with Serge Depatie of Natcan Investment Management Inc.  In the report Mr Depatie reports on the swings of volatility in the global healthcare market. He also gives his view on investment trends in the industry;

Mr. Depatie: An important trend we’re seeing is the, I would say, rejuvenation of biotech drugs in antibody classes. Monoclonal antibodies had a big market expansion in the mid to later 1970s to 1980s, and these drugs are being reformatted in a less toxic and more efficient manner. We’re going to see a new wave of these biotech drugs, which should help the larger players to start off with and also to some extent the small biotechs. The leading player is Amgen (AMGN) there and it acts as a flagship to the industry. They have a new drug called denosumab for pre­vention of bone cancer, which represents potentially over a $5 billion market, which would basically reinvigorate the company and send it on a growth path again. If this drug works, and all in­dications are good and as the expectations become high and the stock appreciates well, it should pull all boats in the sector, in that other companies will also do well. We definitely have increased our activity in the biotech sector in the last year.

Follow us on TWITTER for exclusive content

This entry was posted on Thursday, October 22nd, 2009 at 10:19 am and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.